• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Phase I Study Indicates Pembrolizumab an Option in Heavily Pretreated Hodgkin Lymphoma

Article

A small, early-stage study in patients with Hodgkin lymphoma who had failed multiple treatments or relapsed after stem cell transplant indicates that pembrolizumab could be a favorable treatment option in these patients.

A small, early-stage study in patients with Hodgkin lymphoma who had failed multiple treatments or relapsed after stem cell transplant indicates that pembrolizumab could be a favorable treatment option in these patients.

Preliminary research studies have shown that patients with Hodgkin lymphoma may overexpress the programmed death ligand-1 (PD-1) protein on their cell surface, indicating that the tumors may be dependent on PD-1 for survival, and thus making it an ideal drug target. To test this hypothesis, the KEYNOTE-013 trial enrolled 31 patients with relapsed, refractory Hodgkin lymphoma who had progressed following treatment with brentuximab vedotin. Patients were treated with pembrolizumab every 2 weeks until week 12, and every 8 weeks after, until disease progression. Safety and complete remission (CR) rate were the primary trial endpoints.

Of the 31 patients, 55% had had more than 4 lines of therapy and 71% had relapsed following autologous stem cell transplant. The observed CR rate was 16% (90% CI, 7% to 31%). Nearly half (48%) the patients achieved a partial remission for an overall response rate of 65% (90% CI, 48% to 79%). A majority (70%) of the responses lasted for more than 6 months, with a median follow-up of 17 months.

The most commonly observed adverse events (AEs) were hypothyroidism (16%), diarrhea (16%), nausea (13%), and pneumonitis (10%). Grade 3 AEs were observed in 16% of patients, namely colitis, increased ALT and AST levels, nephrotic syndrome, joint swelling, back pain, and axillary pain. There were no grade 4 treatment-related AEs.

The authors feel that their results are a sufficient prerogative for further studies of pembrolizumab in patients with Hodgkin lymphoma.

The study is published in the November issue of the Journal of Clinical Oncology.

Related Videos
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Dr Guru Sonpavde
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.